Serum levels of insulin-like growth factor-1 and obsessive-compulsive disorder: A case-control study

Neuropsychobiology

Volumn 74, Issue 1, 2016, Pages 15-21

  Rosso, Gianluca ^a   Zanardini, Roberta ^b   Chiodelli, Daniela Francesca ^a   Ferrari, Clarissa ^b   Gennarelli, Massimo ^b,c   Bocchio Chiavetto, Luisella ^b,d  

^a UNIVERSITY OF TURIN   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d ECAMPUS UNIVERSITY   (Italy)

Author keywords

Antidepressants; Depression; Growth hormone; Insulin like growth factor 1; Neurobiology; Neurotrophic factors; Obsessive compulsive disorder; Serotonin reuptake inhibitors; Somatotropic axis; Treatment response

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUVOXAMINE; PAROXETINE; SERTRALINE; SOMATOMEDIN C; IGF1 PROTEIN, HUMAN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; METABOLISM; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER;

ADULT; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 84980383585     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000446918     Document Type: Article

References (55)

1. Anlar B, Sullivan KA, Feldman EL: Insulinlike growth factor-I and central nervous system development. Horm Metab Res 1999; 31: 120-125.
2. Bondy CA, Lee WH LW: Patterns of insulinlike growth factor and IGF receptor gene expression in the brain. Functional implications. Ann NY Acad Sci 1993; 692: 33-43.
3. D Ercol AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G: The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 1996; 13: 227-255.
4. Werther GA, Abate M, Hogg A, Cheesman H, Oldfield B, Hards D, Hudson P, Power B, Freed K, Herington AC: Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization relationship to IGF-I receptors. Mol Endocrinol 1990; 4: 773-778.
5. Torres-Aleman I: Serum growth factors and neuroprotective surveillance. Mol Neurobiol 2000; 21: 153-160.
6. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I: Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor-1. J Neurosci 2005; 25: 10884-10893.
7. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A, Standhardt H, Gotthardt U, Schmider J, Pflaum CD, Heuser I: Insulin-like growth factor-1 plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997; 22: 493-503.
8. Muller EE: Neural control of somatotropic function. Physiol Rev 1987; 3: 962-1053.
9. Rupprecht R, Rupprecht C, Rupprecht M, Noder M, Lesch KP, Mossner J: Effect of glucocorticoids on the regulation of the hypothalamic-pituitary-somatotropic system in depression. J Affect Disord 1989; 17: 9-16.
10. Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M: Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009; 42: 23-28.
11. Liu X, Zhang T, He S, Hong B, Chen Z, Peng D, Wu Y, Wen H, Lin Z, Fang Y, Jiang K: Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res 2014; 218: 54-60.
12. Bezchlibnyk YB, Xu L, Wang JF, Young LT: Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res 2007; 1147: 213-217.
13. Kim YK, NA KS, Hwang JA, Yoon HK, Lee HL, Hahn SW, Lee BH, Jung HY: High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker? J Affect Disord 2013; 151: 738-743.
14. Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M, Ruiz de Azua S, Alberich S, Mosquera F, Matute C: Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 2013; 44: 29-33.
15. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN: Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res 2010; 119: 131-137.
16. Khawaja X, Xu, J, Liang JJ, Barrett JE: Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 2004; 75: 451-460.
17. Anderson MF, Aberg MA, Nilsson M, Eriksson PS: Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res 2002; 134: 115-122.
18. Hoshaw BA, Malberg JE, Lucki I: Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-208.
19. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S: Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007; 32: 2360-2368.
20. Li SX, Liu LY, Xu LZ, Gao L, Wang XF, Zhang JT, Lu L: Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology 2013; 38: 2789-2799.
21. Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A: Dopamine function in obsessivecompulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry 1997;42: 889-897.
22. Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A, Perini G, Carraro C, Gava F: Noradrenergic receptor sensitivity in obsessive compulsive disorder: cortisol response to acute clonidine administration. Psychiatry Res 1997;69: 163-168.
23. Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A: Growth hormone response to growth hormone-releasing hormone stimulation in obsessive-compulsive disorder. Psychiatry Res 1998; 81: 293-299.
24. Kluge K, Schussler P, Weikel J, Dresler M, Zuber V, Querfurt F, Yassouridis A, Steiger A: Altered nocturnal growth hormone (GH) secretion in obsessive compulsive disorder. Psychoneuroendocrinology 2006; 31: 1098-1104.
25. Maina G, Rosso G, Zanardini R, Bogetto F, Gennarelli M, Bocchio-Chiavetto L: Serum levels of brain-derived neurotrophic factor in drug-naive obsessive-compulsive patients: a case-control study. J Affect Disord 2010; 122: 174-178.
26. Carro E, Nunez A, Busiguina S, Torres-Aleman I: Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 2000; 20: 2926-2933.
27. Mattson MP, Maudsley S, Martin B: A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 2004; 3: 445-464.
28. Ding Q, Vaynman S, Akhavan M, Ying Z, Gomez-Pinilla F: Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience 2006; 140: 823-833.
29. Landi S, Ciucci F, Maffei L, Berardi N, Cenni MC: Setting the pace for retinal development: environmental enrichment acts through insulin-like growth factor 1 and brain-derived neurotrophic factor. J Neurosci 2009; 29: 10809-10819.
30. Goodman KW, Price LH, Rasmussen SA: The Yale-Brown Obsessive-Compulsive Scale I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
31. Rosso G, Rigardetto S, Bogetto F, Maina G: A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord 2012; 136: 1365-1371.
32. Maina G, Albert U, Salvi V, Pessina E, Bogetto F: Early-onset obsessive-compulsive disorder and personality disorders in adulthood. Psychiatry Res 2008; 158: 217-225.
33. Rosso G, Albert U, Asinari GF, Bogetto F, Maina G: Stressful life events and obsessivecompulsive disorder: clinical features and symptom dimensions. Psychiatry Res 2012; 197: 259-264.
34. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington, American Psychiatric Press, 1997.
35. First N, Spitzer R, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCIDCV). Washington, American Psychiatric Press, 1997.
36. Karameh WK, Khani M: Intravenous clomipramine for treatment-resistant obsessivecompulsive disorder. Int J Neuropsychopharmacol 2015; 28: 19.
37. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E: Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009; 23: 1047-1055.
38. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E: Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol 2014; 24: 375-380.
39. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P: Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-Analysis. J Clin Psychiatry 2015; 76: 487-498.
40. Trejo JL, Piriz J, Llorens-Martin MV, Fernandez AM, Bolos M, LeRoith D, Nunez A, Torres-Aleman I: Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol Psychiatry 2007; 12: 1118-1128.
41. Hoshaw BA, Malberg JE, Lucki I: Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-208.
42. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S: Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007; 32: 2360-2368.
43. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS: Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009; 198: 366-371.
44. Mills JL, Hediger ML, Molloy CA, Chrousos GP, Manning-Courtney P, Yu KF, Brasington M, England LJ: Elevated levels of growth-related hormones in autism and autism spectrum disorder. Clin Endocrinol (Oxf) 2007; 67: 230-237.
45. Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2014; 20: 212-216.
46. Duric V, Duman RS: Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 2013; 70: 39-53.
47. Leventhal PS, Shelden EA, Kim B, Feldman EL: Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J Biol Chem 1997; 272: 5214-5218.
48. Kim YK, Na KS, Hwang JA, Yoon HK, Lee HJ, Hahn SW, Lee BH, Jung HY: High insulinlike growth factor-1 in patients with bipolar I disorder: a trait marker? J Affect Disord 2013; 151: 738-743.
49. Liu X, Zhang T, He S, Hong B, Chen Z, Peng D, Wu Y, Wen H, Lin Z, Fang Y, Jiang K: Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res 2014; 218: 54-60.
50. Bezchlibnyk YB, Xu L, Wang JF, Young LT: Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res 2007;1147: 213-217.
51. Baldini S, Restani L, Baroncelli L, Coltelli M, Franco MR, Cenni MC, Maffei L, Berardi N: Enriched early life experiences reduce adult anxiety-like behavior in rats: a role for insulin-like growth factor-1. J Neurosci 2013; 33: 11715-11723.
52. Kopczak A, Stalla GK, Uhr M, Lucae S, Hennings J, Ising M, Holsboer F, Kloiber S: IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol 2015; 25: 864-872.
53. Sievers C, Dimopoulou D, Pfister H, Lieb R, Steffin B, Roemmler J, Schopohl J, Mueller M, Schneider HJ, Ising M, Wittchen HU, Stalla GK: Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol (Oxf) 2009; 71: 691-701.
54. Emeny RT, Bidlingmaier M, Lacruz ME, Linkohr B, Peters A, Reincke M, Ladwig KH: Mind over hormones: sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-Age study. Exp Gerontol 2014; 59: 58-64.
55. Van Varsseveld NC, van Bunderen CC, Sohl E, Comijs HC, Penninx BWJH, Lips P, Drent ML: Serum insulin-like growth factor 1 and late-life depression: a population-based study. Psychoneuroendocrinology 2015; 54: 31-40.